HPV16 Oncoproteins Induce MMPs/RECK-TIMP-2 Imbalance in Primary Keratinocytes: Possible Implications in Cervical Carcinogenesis

Imagem de Miniatura
Arquivos
art_LONGATTO FILHO_HPV16_Oncoproteins_Induce_MMPs_RECK_TIMP_2_Imbalance_2012.PDF (618.8 KB)
Citações na Scopus
50
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
CARDEAL, Laura Beatriz da Silva
BOCCARDO, Enrique
TERMINI, Lara
RABACHINI, Tatiana
ANDREOLI, Maria Antonieta
LORETO, Celso di
VILLA, Luisa Lina
MARIA-ENGLER, Silvya Stuchi
Citação
PLOS ONE, v.7, n.3, article ID e33585, 9p, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Cervical cancer is the third most common cancer in women worldwide. Persistent infection with high-risk HPV types, principally HPV16 and 18 is the main risk factor for the development of this malignancy. However, the onset of invasive tumor occurs many years after initial exposure in a minority of infected women. This suggests that other factors beyond viral infection are necessary for tumor establishment and progression. Tumor progression is characterized by an increase in secretion and activation of matrix metalloproteinases (MMPs) produced by either the tumor cells themselves or tumor-associated fibroblasts or macrophages. Increased MMPs expression, including MMP-2, MMP-9 and MT1-MMP, has been observed during cervical carcinoma progression. These proteins have been associated with degradation of ECM components, tumor invasion, metastasis and recurrence. However, few studies have evaluated the interplay between HPV infection and the expression and activity of MMPs and their regulators in cervical cancer. We analyzed the effect of HPV16 oncoproteins on the expression and activity of MMP-2, MMP-9, MT1-MMP, and their inhibitors TIMP-2 and RECK in cultures of human keratinocytes. We observed that E7 expression is associated with increased pro-MMP-9 activity in the epithelial component of organotypic cultures, while E6 and E7 oncoproteins co-expression down-regulates RECK and TIMP-2 levels in organotypic and monolayers cultures. Finally, a study conducted in human cervical tissues showed a decrease in RECK expression levels in precancer and cancer lesions. Our results indicate that HPV oncoproteins promote MMPs/ RECK-TIMP-2 imbalance which may be involved in HPV-associated lesions outcome.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/1606
Referências
  1. Akgul B, 2011, MED MICROBIOL IMMUN, V200, P127, DOI 10.1007/s00430-011-0183-4
  2. Boccardo E, 2004, VIROLOGY, V328, P233, DOI 10.1016/j.virol.2004.07.026
  3. Branca M, 2006, ANTICANCER RES, V26, P1543
  4. Brummer O, 2002, GYNECOL ONCOL, V84, P222, DOI 10.1006/gyno.2001.6413
  5. Clark JCM, 2007, CANCER METAST REV, V26, P675, DOI 10.1007/s10555-007-9093-8
  6. Correa TCS, 2010, J CELL BIOCHEM, V110, P52, DOI 10.1002/jcb.22472
  7. DASILVA CM, 2006, BIOCH CELL BIOL, V84, P713
  8. Dong QA, 2010, INT J EXP PATHOL, V91, P368, DOI 10.1111/j.1365-2613.2010.00724.x
  9. Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
  10. Fejzo MS, 2011, GENE CHROMOSOME CANC, V50, P434, DOI 10.1002/gcc.20868
  11. Furumoto K, 2001, HEPATOLOGY, V33, P189, DOI 10.1053/jhep.2001.21048
  12. Gaiotto MAM, 2004, AM J OBSTET GYNECOL, V190, P1278, DOI 10.1016/j.ajog.2003.12.017
  13. Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513
  14. Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978
  15. Howie HL, 2009, VIROLOGY, V384, P324, DOI 10.1016/j.virol.2008.11.017
  16. International Agency for Research on Cancer (WHO), 2007, IARC MON EV CARC RIS, V90
  17. Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
  18. Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
  19. Liu LT, 2003, ONCOGENE, V22, P8263, DOI 10.1038/sj.onc.1207157
  20. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  21. Masui T, 2003, CLIN CANCER RES, V9, P1779
  22. McLaughlin-Drubin ME, 2009, VIRUS RES, V143, P195, DOI 10.1016/j.virusres.2009.06.008
  23. Min W, 2009, INT J GYNECOL CANCER, V19, P547, DOI 10.1111/IGC.0b013e3181a44c68
  24. Morioka Y, 2009, ONCOGENE, V28, P1454, DOI 10.1038/onc.2008.486
  25. Nair SA, 2003, J CANCER RES CLIN, V129, P123, DOI 10.1007/s00432-002-0411-9
  26. NUOVO GJ, 1995, CANCER RES, V55, P267
  27. Oh J, 2004, CANCER RES, V64, P9062, DOI 10.1158/0008-5472.CAN-04-1981
  28. Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9
  29. Oh J, 2006, ONCOGENE, V25, P4230, DOI 10.1038/sj.onc.1209444
  30. Pahler J, 2008, NEOPLASIA, V10, P329, DOI 10.1593/neo.07871
  31. Riddick ACP, 2005, BRIT J CANCER, V92, P2171, DOI 10.1038/sj.bjc.6602630
  32. Sasahara RM, 2002, CANCER DETECT PREV, V26, P435, DOI 10.1016/S0361-090X(02)00123-X
  33. Schlecht NF, 2001, JAMA-J AM MED ASSOC, V286, P3106, DOI 10.1001/jama.286.24.3106
  34. Schroer N, 2011, CANCER RES, V71, P87, DOI 10.1158/0008-5472.CAN-10-2193
  35. Sheu Bor-Ching, 2003, Cancer Research, V63, P6537
  36. Span PN, 2003, CANCER, V97, P2710, DOI 10.1002/cncr.11395
  37. Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347
  38. Stetler-Stevenson WG, 2008, CANCER METAST REV, V27, P57, DOI 10.1007/s10555-007-9105-8
  39. Takagi S, 2009, CANCER RES, V69, P1502, DOI 10.1158/0008-5472.CAN-08-2635
  40. Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221
  41. Takenaka K, 2004, EUR J CANCER, V40, P1617, DOI 10.1016/j.ejca.2004.02.028
  42. Takeuchi T, 2004, CLIN CANCER RES, V10, P5572, DOI 10.1158/1078-0432.CCR-03-0656
  43. Theret N, 1999, HEPATOLOGY, V30, P462, DOI 10.1002/hep.510300236
  44. Yoshida S, 2008, J VIROL, V82, P8820, DOI 10.1128/JVI.02363-07
  45. Zhai YL, 2005, CANCER RES, V65, P6543, DOI 10.1158/0008-5472.CAN-05-0231

Coleções
Artigos e Materiais de Revistas Científicas - LIM/14